| Study of ESG401 in Adults With Solid Tumors (NCT04892342) | Shanghai Escugen Biotechnology Co., Ltd | 2021-09-14 |
| Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (NCT04915755) | GlaxoSmithKline | 2021-06-28 |
| Early Rehabilitation for Breast Cancer - A Randomized Control Trial (NCT04777786) | University of South Carolina | 2021-04-01 |
| Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA (NCT05814224) | Centro di Riferimento Oncologico - Aviano | 2018-05-22 |
| Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer (NCT03329937) | Tesaro, Inc. | 2018-04-12 |
| Pre- Versus Postoperative Accelerated Partial Breast Irradiation (NCT02913729) | The Netherlands Cancer Institute | 2016-11-10 |
| Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer (NCT03273595) | Xijing Hospital | 2016-07-01 |
| Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer (NCT02213042) | Novartis Pharmaceuticals | 2014-10-24 |
| Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients (NCT01782651) | GlaxoSmithKline | 2014-08-01 |
| A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (NCT01905592) | Tesaro, Inc. | 2014-02-25 |
| Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer (NCT02063893) | Fuda Cancer Hospital, Guangzhou | 2014-01-01 |
| A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer (NCT01815294) | Janssen Research & Development, LLC | 2013-05-01 |
| Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer (NCT01476111) | GlaxoSmithKline | 2011-12-01 |
| Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer (NCT01498588) | Emory University | 2011-11-01 |
| A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer (NCT01137994) | GlaxoSmithKline | 2011-10-01 |
| A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer (NCT01160211) | Novartis Pharmaceuticals | 2011-05-05 |
| Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer (NCT01220128) | GlaxoSmithKline | 2011-04-11 |
| Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer (NCT01205217) | GlaxoSmithKline | 2010-12-01 |
| Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC (NCT01138046) | GlaxoSmithKline | 2010-04-01 |
| Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer (NCT01118624) | Acrotech Biopharma Inc. | 2010-03-01 |
| A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib (NCT00996762) | GlaxoSmithKline | 2009-11-12 |
| Treatment With Pazopanib for Neoadjuvant Breast Cancer (NCT00849472) | GlaxoSmithKline | 2009-07-01 |
| A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer (NCT00849329) | GlaxoSmithKline | 2009-03-10 |
| A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients (NCT00821054) | GlaxoSmithKline | 2009-03-06 |
| Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents (NCT00790816) | Novartis Pharmaceuticals | 2008-10-01 |
| A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors (NCT00722293) | GlaxoSmithKline | 2008-07-08 |
| Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC (NCT00709761) | Novartis Pharmaceuticals | 2008-07-02 |
| Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells (NCT00820924) | GlaxoSmithKline | 2008-06-01 |
| Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects (NCT00709618) | GlaxoSmithKline | 2008-06-01 |
| Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer (NCT00650910) | GlaxoSmithKline | 2008-04-23 |
| Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy (NCT00661531) | Georgetown University | 2008-04-01 |
| Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study (NCT00553358) | Novartis Pharmaceuticals | 2008-01-05 |
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer (NCT00558103) | GlaxoSmithKline | 2007-12-01 |
| Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer (NCT00479856) | GlaxoSmithKline | 2007-11-01 |
| Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. (NCT00524303) | GlaxoSmithKline | 2007-08-01 |
| Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China (NCT00508274) | Novartis Pharmaceuticals | 2007-07-18 |
| Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer (NCT00477464) | GlaxoSmithKline | 2007-06-01 |
| ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D (NCT00490139) | Novartis Pharmaceuticals | 2007-05-16 |
| Brain Metastases In ErbB2-Positive Breast Cancer (NCT00437073) | GlaxoSmithKline | 2007-05-01 |
| Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer (NCT00422903) | GlaxoSmithKline | 2007-04-01 |
| Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer. (NCT00367471) | Novartis Pharmaceuticals | 2006-12-07 |
| Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer (NCT00429299) | GlaxoSmithKline | 2006-08-01 |
| Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer (NCT00374322) | GlaxoSmithKline | 2006-08-01 |
| EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer (NCT00338247) | Novartis | 2006-07-01 |
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer (NCT00347919) | GlaxoSmithKline | 2006-07-01 |
| Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer (NCT00356811) | GlaxoSmithKline | 2006-05-01 |
| Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB) (NCT00388076) | GlaxoSmithKline | 2006-04-28 |
| GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer (NCT00371488) | GlaxoSmithKline | 2006-04-06 |
| Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 (NCT00281658) | Novartis Pharmaceuticals | 2006-01-02 |
| ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib (NCT00272987) | Novartis Pharmaceuticals | 2005-12-13 |
| Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer (NCT00263588) | Novartis Pharmaceuticals | 2005-12-02 |
| GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer (NCT00320411) | GlaxoSmithKline | 2005-11-28 |
| To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients (NCT00258050) | GlaxoSmithKline | 2005-11-21 |
| Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer (NCT00320385) | GlaxoSmithKline | 2005-11-01 |
| GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer (NCT00251433) | Novartis Pharmaceuticals | 2005-09-26 |
| Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer (NCT00111787) | GlaxoSmithKline | 2005-04-11 |
| Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer (NCT00140738) | GlaxoSmithKline | 2005-03-10 |
| Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer (NCT00105950) | GlaxoSmithKline | 2005-03-01 |
| Rollover Study Of Lapatinib In Cancer Patients (NCT00169533) | GlaxoSmithKline | 2004-08-19 |
| Study Of Ispinesib In Subjects With Breast Cancer (NCT00089973) | GlaxoSmithKline | 2004-06-30 |
| GW572016 In Patients With Advanced Or Metastatic Breast Cancer (NCT00462956) | GlaxoSmithKline | 2004-06-30 |
| Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer (NCT00359190) | GlaxoSmithKline | 2004-06-29 |
| Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer (NCT00089999) | GlaxoSmithKline | 2004-06-01 |
| GW572016 For Treatment Of Refractory Metastatic Breast Cancer (NCT00062686) | GlaxoSmithKline | 2003-11-01 |
| Effects Of GW572016 In Combination With Docetaxel (TAXOTERE) (NCT00148902) | GlaxoSmithKline | 2003-04-28 |
| A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer (NCT00058526) | GlaxoSmithKline | 2003-03-20 |
| Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin. (NCT00051103) | GlaxoSmithKline | 2002-10-01 |